Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-HB-IPV
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-HB-IPV is a pentavalent combination vaccine designed to provide protection against five infectious diseases: diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus. This vaccine simplifies the immunization schedule by combining multiple antigens into a single injection, aiming to enhance compliance and facilitate broader vaccine acceptance. It was developed by GlaxoSmithKline (GSK).
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)Poliovirus type 1 D-antigenPoliovirus type 3 D-antigenHBsAg (Hepatitis B surface antigen)TLR7/TLR8 (Toll-like receptor 7 and Toll-like receptor 8)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTaP-HB-IPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-HB-IPV.